Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -66.80% is 63% below its 5-year average of -40.99%, near the low end of its 5-year range (-68.82%–-18.29%).
17.30% below its 12-month average of -56.95%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): -14.41%.
RETURN ON ASSETS (ROA)
-66.80%
RETURN ON ASSETS (ROA) AVG TTM
-56.95%
RETURN ON ASSETS (ROA) AVG 3Y
-50.95%
RETURN ON ASSETS (ROA) AVG 5Y
-40.99%
RETURN ON ASSETS (ROA) AVG 10Y
-35.01%
RETURN ON ASSETS (ROA) AVG 15Y
-21.59%
RETURN ON ASSETS (ROA) AVG 20Y
N/A
CURRENT VS TTM AVG
-17.30%
CURRENT VS 3Y AVG
-31.10%
CURRENT VS 5Y AVG
-62.96%
CURRENT VS 10Y AVG
-90.80%
CURRENT VS 15Y AVG
-209.45%
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-26.90%
median of 504 covered companies
CURRENT VS SECTOR MEDIAN
-148.33%
vs the sector median at left
Adicet Bio, Inc.
Market Cap
$60.48M
Return on Assets (ROA)
-66.80%
TTM Avg
-56.95%
3Y Avg
-50.95%
5Y Avg
-40.99%
Market Cap
$60.29M
Return on Assets (ROA)
-128.88%
TTM Avg
-89.84%
3Y Avg
-89.26%
5Y Avg
-80.42%
Market Cap
$60.78M
Return on Assets (ROA)
-118.15%
TTM Avg
-138.13%
3Y Avg
-224.99%
5Y Avg
-221.92%
Market Cap
$61.77M
Return on Assets (ROA)
-44.47%
TTM Avg
-42.63%
3Y Avg
-230.85%
5Y Avg
-167.04%
Market Cap
$58.43M
Return on Assets (ROA)
-37.05%
TTM Avg
-34.36%
3Y Avg
-41.63%
5Y Avg
-37.74%
Market Cap
$63.98M
Return on Assets (ROA)
-87.09%
TTM Avg
-130.17%
3Y Avg
-272.35%
5Y Avg
-217.34%
Market Cap
$56.54M
Return on Assets (ROA)
-98.94%
TTM Avg
-57.19%
3Y Avg
-57.75%
5Y Avg
-128.29%
Market Cap
$64.56M
Return on Assets (ROA)
-5.05%
TTM Avg
-7.03%
3Y Avg
-4.31%
5Y Avg
-4.67%
Market Cap
$65.08M
Return on Assets (ROA)
-162.91%
TTM Avg
-58.42%
3Y Avg
-64.67%
5Y Avg
-61.98%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Adicet Bio, Inc. (ACET) | $60.48M | -66.80% | -56.95% | -50.95% | -40.99% |
| Fractyl Health, Inc. (GUTS)vs › | $60.29M | -128.88% | -89.84% | -89.26% | -80.42% |
| MiNK Therapeutics, Inc. (INKT)vs › | $60.78M | -118.15% | -138.13% | -224.99% | -221.92% |
| Kalaris Therapeutics Inc (KLRS)vs › | $61.77M | -44.47% | -42.63% | -230.85% | -167.04% |
| Boundless Bio, Inc. (BOLD)vs › | $58.43M | -37.05% | -34.36% | -41.63% | -37.74% |
| Cingulate Inc. (CING)vs › | $63.98M | -87.09% | -130.17% | -272.35% | -217.34% |
| Connect Biopharma Holdings Limited (CNTB)vs › | $56.54M | -98.94% | -57.19% | -57.75% | -128.29% |
| InterCure Ltd. (INCR)vs › | $64.56M | -5.05% | -7.03% | -4.31% | -4.67% |
| Gossamer Bio, Inc. (GOSS)vs › | $65.08M | -162.91% | -58.42% | -64.67% | -61.98% |
| Aldeyra The (ALDX)vs › | $55.72M | -48.49% | -50.18% | -39.97% | -38.29% |
ROA
-66.8%
ROE
-82.4%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | -60.72% |
| 2024-12-31 | -53.18% |
| 2023-12-31 | -68.82% |
| 2022-12-31 | -21.10% |
| 2021-12-31 | -18.29% |
| 2020-12-31 | -23.84% |
| 2019-12-31 | -34.49% |
| 2018-12-31 | -8.46% |
| 2017-06-30 | -61.20% |
| 2016-06-30 | 0.00% |
| 2015-06-30 | 5.92% |
| 2014-06-30 | 4.77% |
| 2013-06-30 | 6.90% |
| 2012-06-30 | 5.67% |
| 2011-06-30 | 3.04% |
| 2010-06-30 | 3.04% |
| 2009-06-30 | 4.56% |
| 2008-06-30 | 6.56% |
